According to the latest report by IMARC Group, titled, “Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” The global metabolomics market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2027, exhibiting a CAGR of 12% during 2022-2027.
Metabolomics is the study and analysis of small molecules present in cells, biofluids, tissues, and organisms. It includes various steps, such as the acquisition, separation, detection of analytes, and data mining and extraction, and analysis. It involves various analytic techniques, such as nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS). It serves as an effective tool in the diagnosis of a disease and facilitates the prediction of treatment response and survival. As it is also employed to detect the recurrence of a disease after therapy, metabolomics is gaining traction in biomarker and drug discovery, toxicology, nutrigenomics, and personalized medicines across the globe.
Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/metabolomics-market/requestsample
Metabolomics Market Trends and Drivers:
At present, the growing global geriatric population and increasing prevalence of cancer and various cardiovascular and neurological disorders represent one of the key factors positively influencing the market. In addition, rising cases of inborn errors of metabolism (IEM), such as fructose intolerance, maple syrup urine disease (MSUD), fatty acid oxidation defects, mitochondrial disorders, and phenylketonuria (PKU) are catalyzing the demand for untargeted metabolomics for IEM screening worldwide. In line with this, increasing investments in research and development (R&D) activities and rising integration of machine learning (ML) algorithms with metabolomics to identify weight gain biomarkers is fueling the growth of the market.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
- Agilent Technologies, Inc. (A)
- Biocrates Life Sciences AG
- Bio-Rad Laboratories, Inc. (BIO)
- Bruker Corporation (BRKR)
- Danaher Corporation (DHR)
- HUMAN METABOLOME TECHNOLOGIES I (6090.T)
- Metabolon Inc.
- SHIMADZU CORP (SHMZF)
- Thermo Fisher Scientific Inc.
- Waters Corporation, etc.
Metabolomics Market 2022-2027 Competitive Analysis and Segmentation:
The report has segmented the market based on product, indication and application.
Insights on Market Segmentation:
Market Breakup by Product:
- Metabolomics Instruments
- Metabolomics Bioinformatics Tools and Services
Market Breakup by Indication:
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Others
Market Breakup by Application:
- Biomarker and Drug Discovery
- Toxicology
- Nutrigenomics
- Personalized Medicine
- Others
Market Segmentation by Region:
- North America
- Asia Pacific
- Europe
- United Kingdom
- Latin America
- Middle East and Africa
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/metabolomics-market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Website: https://www.imarcgroup.com
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800